📰 A 239 Ve News
A 239 Ve News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from A 239 Ve. Real-time updates on events, politics, business and more.
May 12, 2023
Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozoleMedian
April 26, 2023
Data at EBMT show primary endpoint met - estimated* 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2 g/dL or more hemoglobin-level increase from baseline
December 11, 2022
WASHINGTON (dpa-AFX) - AbbVie (ABBV) said the exploratory analysis from Cohort 3 of the Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor-naïve